Every cancer patient deserves the right treatment
for their individual form of cancer.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Extended Partnership with Werfen strengthens 2cureX’s Iberian distribution network
For over 2 decades, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat®, 2cureX makes microtumor testing an operational reality to serve you and your cancer clinic.
IndiTreat tests determine the sensitivity to different drug regimens for certain types of metastic colorectral cancer. Ask your doctor if it is possible to consider IndiTreat for your cancer.
Change of distribution partner in Portugal
2cureX expands distribution of IndiTreat® to Romania
2cureX publishes interim report for the second quarter and first half of 2022
2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret 2022
Get notified on mail, when news or press releases are posted on our website